Cargando…
RF23 | PSAT258 Comparable Bioavailability of a Novel Levothyroxine Solution taken 10 or 30 minutes prior to a High-Fat, High-Calorie Breakfast
Levothyroxine (LT4) is the recommended treatment for hypothyroidism and the second most prescribed medication in the US. Several formulations are available, however most patients take LT4 tablets. Evidence suggests that absorption of levothyroxine tablets is decreased when taken with food, especiall...
Autores principales: | Washington, Kris, Baron, Michelle, Vandse, Sunil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627558/ http://dx.doi.org/10.1210/jendso/bvac150.1771 |
Ejemplares similares
-
RF23 | PSAT259 Comparable Bioavailability of a Novel Levothyroxine Solution when Administered with Coffee
por: Washington, Kris, et al.
Publicado: (2022) -
PSAT364 High-Dose Levothyroxine to Exclude Malabsorption as a Cause of Refractory Hypothyroidism in Hospitalized Patients: Two Cases
por: Majumdar, Sachin, et al.
Publicado: (2022) -
RF23 | PSAT365 An Open-Label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors
por: Sachmechi, Issac, et al.
Publicado: (2022) -
A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes Before a High-Fat High-Calorie Meal
por: Ducharme, Murray, et al.
Publicado: (2022) -
ODP476 Does Levothyroxine Intake at Breakfast Matter for Patients With Hypothyroidism? A Meta- Analysis of Randomized Control Trials
por: Cheng, Ce, et al.
Publicado: (2022)